XML 45 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)
3 Months Ended
Sep. 28, 2016
USD ($)
Agreement
$ / shares
shares
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2018
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Proceeds from the issuance of common stock   $ 60,521,729    
Revenues   34,657,896 $ 3,509,821  
Contract liabilities   $ 124,925,638   $ 600
Type of Revenue [Extensible List]   arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember  
Common Stock Purchase Agreement | Amgen        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Sep. 28, 2016      
Shares issued | shares 3,002,793      
Stock issued, price per share | $ / shares $ 7.16      
Collaboration and License agreements | Amgen        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Sep. 28, 2016      
Number of agreements | Agreement 2      
ARO-AMG1 Agreement | Amgen        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Additional amount of common stock shares agreed to sell upon exercise of option $ 5,000,000      
Number of trading days, used to calculate share price of Common Stock, surrounding option exercise date 30 days      
Collaboration and License agreements | Amgen        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Cash received as due under collaboration agreement $ 35,000,000      
Proceeds from the issuance of common stock 21,500,000      
Collaboration and License agreements | Maximum | Amgen        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Option payments, and development, regulatory and sales milestone payments. $ 617,000,000      
AMG 890 (ARO-LPA) and ARO-AMG1 Agreement | Amgen        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues   $ 0 $ 3,500,000  
Contract liabilities   100,000    
Contract assets   $ 0    
Type of Revenue [Extensible List]   us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember